Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that ...

Researchers at the University of Cologne and University Hospital Cologne have determined that the novel mRNA-based COVID-19 ...

Researchers have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against potential ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...

Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...

Our immune systems develop to recognize what is foreign within our bodies. As immune cells are generated in the bone marrow ...

Innate Pharma S.A. (($FR:IPH)) has held its Q4 earnings call. Read on for the main highlights of the call. Innate Pharma’s recent earnings call ...

FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK ...

Manuscript Summary Submission Deadline 30 May 2025 | Manuscript Submission Deadline 29 June 2025 | Manuscript Extension Submission Deadline 30 July 2025 ...

Non-genetic resistance is associated with resistant cancer cells that have innate or acquired drug resistance traits. These ...

Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics ...